Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Cost-Effectiveness of Nirsevimab for Prevention of Respiratory Syncytial Virus Outcomes in Infants

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HE0045-000

Question

  1. What is the cost-effectiveness of nirsevimab for the prevention of respiratory syncytial virus outcomes in infants?

Files

Cost-Effectiveness of Nirsevimab for Prevention of Respiratory Syncytial Virus … View PDF
Last Updated : October 19, 2023